Efficacy and safety of anti-PD-L1 antibody in NSCLC patients who previously treated with anti PD-1 antibodies

Conclusions: Only selected patients benefited from atezolizumab after anti-PD-1 antibody.

Source: European Respiratory Journal - November 20, 2019 Category: Respiratory Medicine Authors: Fujita, K., Uchida, N., Yamamoto, Y., Kanai, O., Okamura, M., Nakatani, K., Mio, T. Tags: Lung cancer Source Type: research